Published by
The Street
The Street
By PR Newswire SUZHOU, China, Dec. 21, 2021 /PRNewswire/ — CStone Pharmaceuticals (the ” Company” or ” CStone”) is pleased to announce that the National Medical Products Administration (” NMPA”) of China has approved the new drug application (” NDA”) of anti-PD-L1 monoclonal antibody Cejemly ® (sugemalimab) in combination with chemotherapy for treatment-naïve metastatic (stage IV) non-small cell lung cancer (” non-small cell lung caner” or ” NSCLC”) patients. Key Highlights Anti-PD-L1 monoclonal antibody Cejemly ® approved in combination with pemetrexed and carboplatin as first-line treatment…